News

Aruvant Appoints William Chou as Chief Executive Officer

Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia Chou previously led the development and approval of Kymriah® for diffuse large B-cell lymphoma He...